FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899821434> ?p ?o ?g. }

• W2899821434 endingPage "290" @default.
• W2899821434 startingPage "276" @default.
• W2899821434 abstract "Objective To briefly update and correct the available data on anti‐calcitonin gene‐related peptide (CGRP) therapies for headache since the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Background CGRP is a target for primary headache therapies. Methods The author briefly reviews the new data and publications on gepants and anti‐CGRP and anti‐CGRP receptor monoclonal antibodies since the writing of his previous review in May 2018, with an emphasis on data provided at the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Results The US Food and Drug Administration (FDA) approved erenumab‐aooe, an anti‐CGRP receptor monoclonal antibody, for the prevention of migraine on May 17, 2018. On September 14, 2018, the FDA approved fremanezumab‐vfrm and on September 26, 2018, the FDA approved galcanezumab‐gnlm, both anti‐CGRP ligand monoclonal antibodies for the prevention of migraine. Galcanezumab showed effectiveness in preventing episodic cluster headache as well, although has not yet been submitted to the FDA for this indication. Both galcanezumab and fremanezumab failed to prevent chronic cluster headache. Eptinezumab will likely be submitted to the FDA for prevention of migraine later in 2018. Two gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the FDA for this indication. A press release with data on the effectiveness of daily atogepant in migraine prevention provides some details. An announcement at the meeting suggests daily rimegepant will be tested for prevention as well. Conclusions The development of anti‐CGRP therapies opens a new era in the acute and preventive treatment of primary headache disorders." @default.
• W2899821434 created "2018-11-16" @default.
• W2899821434 creator A5064341657 @default.
• W2899821434 date "2018-11-01" @default.
• W2899821434 modified "2023-10-18" @default.
• W2899821434 title "Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018" @default.
• W2899821434 cites W2608751463 @default.
• W2899821434 cites W2748627085 @default.
• W2899821434 cites W2768357559 @default.
• W2899821434 cites W2801085490 @default.
• W2899821434 cites W2803715733 @default.
• W2899821434 cites W2805181790 @default.
• W2899821434 cites W2805937849 @default.
• W2899821434 cites W2892069777 @default.
• W2899821434 cites W2893863004 @default.
• W2899821434 doi "https://doi.org/10.1111/head.13417" @default.
• W2899821434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30403405" @default.
• W2899821434 hasPublicationYear "2018" @default.
• W2899821434 type Work @default.
• W2899821434 sameAs 2899821434 @default.
• W2899821434 citedByCount "46" @default.
• W2899821434 countsByYear W28998214342019 @default.
• W2899821434 countsByYear W28998214342020 @default.
• W2899821434 countsByYear W28998214342021 @default.
• W2899821434 countsByYear W28998214342022 @default.
• W2899821434 countsByYear W28998214342023 @default.
• W2899821434 crossrefType "journal-article" @default.
• W2899821434 hasAuthorship W2899821434A5064341657 @default.
• W2899821434 hasConcept C118303440 @default.
• W2899821434 hasConcept C126322002 @default.
• W2899821434 hasConcept C159654299 @default.
• W2899821434 hasConcept C163170386 @default.
• W2899821434 hasConcept C170493617 @default.
• W2899821434 hasConcept C203014093 @default.
• W2899821434 hasConcept C2777942821 @default.
• W2899821434 hasConcept C2778541695 @default.
• W2899821434 hasConcept C2779627488 @default.
• W2899821434 hasConcept C2910587157 @default.
• W2899821434 hasConcept C512399662 @default.
• W2899821434 hasConcept C535046627 @default.
• W2899821434 hasConcept C542903549 @default.
• W2899821434 hasConcept C71924100 @default.
• W2899821434 hasConcept C98274493 @default.
• W2899821434 hasConceptScore W2899821434C118303440 @default.
• W2899821434 hasConceptScore W2899821434C126322002 @default.
• W2899821434 hasConceptScore W2899821434C159654299 @default.
• W2899821434 hasConceptScore W2899821434C163170386 @default.
• W2899821434 hasConceptScore W2899821434C170493617 @default.
• W2899821434 hasConceptScore W2899821434C203014093 @default.
• W2899821434 hasConceptScore W2899821434C2777942821 @default.
• W2899821434 hasConceptScore W2899821434C2778541695 @default.
• W2899821434 hasConceptScore W2899821434C2779627488 @default.
• W2899821434 hasConceptScore W2899821434C2910587157 @default.
• W2899821434 hasConceptScore W2899821434C512399662 @default.
• W2899821434 hasConceptScore W2899821434C535046627 @default.
• W2899821434 hasConceptScore W2899821434C542903549 @default.
• W2899821434 hasConceptScore W2899821434C71924100 @default.
• W2899821434 hasConceptScore W2899821434C98274493 @default.
• W2899821434 hasIssue "S3" @default.
• W2899821434 hasLocation W28998214341 @default.
• W2899821434 hasLocation W28998214342 @default.
• W2899821434 hasOpenAccess W2899821434 @default.
• W2899821434 hasPrimaryLocation W28998214341 @default.
• W2899821434 hasRelatedWork W2591456584 @default.
• W2899821434 hasRelatedWork W2768357559 @default.
• W2899821434 hasRelatedWork W2782073995 @default.
• W2899821434 hasRelatedWork W2943954338 @default.
• W2899821434 hasRelatedWork W3203319757 @default.
• W2899821434 hasRelatedWork W3207819762 @default.
• W2899821434 hasRelatedWork W4241015566 @default.
• W2899821434 hasRelatedWork W4362668325 @default.
• W2899821434 hasRelatedWork W4378349310 @default.
• W2899821434 hasRelatedWork W4386825598 @default.
• W2899821434 hasVolume "58" @default.
• W2899821434 isParatext "false" @default.
• W2899821434 isRetracted "false" @default.
• W2899821434 magId "2899821434" @default.
• W2899821434 workType "article" @default.